Home / Healthcare / Stocks Buzz: Trovagene, Inc. (NASDAQ: TROV)

Stocks Buzz: Trovagene, Inc. (NASDAQ: TROV)

Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, declared recently that is has formally engaged PRA Health Sciences, a leading, global contract research organization (CRO), to conduct Trovagene’s Phase 1b/2 clinical trial of PCM-075, a polo-like kinase 1 (PLK1) inhibitor, in patients with acute myeloid leukemia (AML).
Trovagene filed an Investigational New Drug (IND) application and protocol for PCM-075 to the FDA, and subsequently plans to initiate a Phase 1b/2 study that will assess the safety, tolerability, dose and scheduling, and preliminary efficacy of PCM-075 in patients with acute myeloid leukemia (AML). PRA will assist Trovagene in clinical site recruitment, clinical operations and regulatory proceedings for the development of PCM-075 in AML. PRA has strong experience in the clinical development of investigational drugs having worked on nearly 80 hematological clinical trials in the past five years.
“We are excited to begin our clinical study of PCM-075 and to have the opportunity to partner with PRA and leverage their extensive experience in conducting AML trials,” said Bill Welch, Chief Executive Officer of Trovagene. “We look forward to generating clinical data that we believe will assess the safety, tolerability, and anti-leukemic activity of PCM-075 in a hematological malignancy.”

Check Also

News Recap: Twitter, Inc. (NYSE: TWTR)

Twitter, Inc. (NYSE: TWTR) recently declared the appointment of Ned Segal as Chief Financial Officer …

Leave a Reply

Your email address will not be published. Required fields are marked *